Javier Salvador-Bofill1, Sonia Molina-Pinelo2,3,4, Mª Luisa Pecero1. 1. Unit of Integral Oncology, Instituto de Biomedicina de Sevilla (IBIS) (HUVR, CSIC, Universidad de Sevilla), Seville, Spain. 2. Unit of Integral Oncology, Instituto de Biomedicina de Sevilla (IBIS) (HUVR, CSIC, Universidad de Sevilla), Seville, Spain. smolina-ibis@us.es. 3. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. smolina-ibis@us.es. 4. Instituto de Biomedicina de Sevilla (IBIS), Campus Hospital Universitario Virgen del Rocío, Avda. Manuel Siurot, s/n, 41013, Seville, Spain. smolina-ibis@us.es.
Abstract
BACKGROUND: Current therapeutic strategies that are used to combat breast cancer vary widely and largely depend on its clinicopathological features, including tumor subtype, size, stage, lymph node involvement, the presence of hormone receptors and/or HER2, as well as the degree of proliferative activity. Recent work has focused on improving our knowledge on the molecular mechanisms that underlie this complex disease. Most of the human genome is transcribed into RNAs that do not encode proteins. These noncoding RNAs may act as mediators in the regulation of gene expression. Based on their size and function, noncoding RNAs are classified into small noncoding RNAs (sncRNAs) and long noncoding RNAs (lncRNAs). LncRNAs have been found to play key roles in relevant biological processes, including breast cancer. As such, lncRNAs have been proposed as diagnostic and prognostic biomarkers, as predictive biomarkers and as putative therapeutic targets. CONCLUSIONS: In this review, we discuss the potential application of lncRNAs for the monitoring and treatment of breast cancer. We conclude that lncRNAs play important roles in the pathophysiology of this disease and may serve as putative therapeutic targets. As such, tumor-specific lncRNAs may be instrumental for improving current breast cancer clinical practices.
BACKGROUND: Current therapeutic strategies that are used to combat breast cancer vary widely and largely depend on its clinicopathological features, including tumor subtype, size, stage, lymph node involvement, the presence of hormone receptors and/or HER2, as well as the degree of proliferative activity. Recent work has focused on improving our knowledge on the molecular mechanisms that underlie this complex disease. Most of the human genome is transcribed into RNAs that do not encode proteins. These noncoding RNAs may act as mediators in the regulation of gene expression. Based on their size and function, noncoding RNAs are classified into small noncoding RNAs (sncRNAs) and long noncoding RNAs (lncRNAs). LncRNAs have been found to play key roles in relevant biological processes, including breast cancer. As such, lncRNAs have been proposed as diagnostic and prognostic biomarkers, as predictive biomarkers and as putative therapeutic targets. CONCLUSIONS: In this review, we discuss the potential application of lncRNAs for the monitoring and treatment of breast cancer. We conclude that lncRNAs play important roles in the pathophysiology of this disease and may serve as putative therapeutic targets. As such, tumor-specific lncRNAs may be instrumental for improving current breast cancer clinical practices.
Entities:
Keywords:
Breast cancer; Chemotherapy; Endocrine therapy; LncRNAs; Radiotherapy; Targeted therapy
Authors: Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol Journal: J Clin Invest Date: 2011-07 Impact factor: 14.808
Authors: Mei-Yin C Polley; Samuel C Y Leung; Dongxia Gao; Mauro G Mastropasqua; Lila A Zabaglo; John M S Bartlett; Lisa M McShane; Rebecca A Enos; Sunil S Badve; Anita L Bane; Signe Borgquist; Susan Fineberg; Ming-Gang Lin; Allen M Gown; Dorthe Grabau; Carolina Gutierrez; Judith C Hugh; Takuya Moriya; Yasuyo Ohi; C Kent Osborne; Frédérique M Penault-Llorca; Tammy Piper; Peggy L Porter; Takashi Sakatani; Roberto Salgado; Jane Starczynski; Anne-Vibeke Lænkholm; Giuseppe Viale; Mitch Dowsett; Daniel F Hayes; Torsten O Nielsen Journal: Mod Pathol Date: 2015-02-20 Impact factor: 7.842
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Christos Sotiriou; Soek-Ying Neo; Lisa M McShane; Edward L Korn; Philip M Long; Amir Jazaeri; Philippe Martiat; Steve B Fox; Adrian L Harris; Edison T Liu Journal: Proc Natl Acad Sci U S A Date: 2003-08-13 Impact factor: 11.205
Authors: Romualdo Barroso-Sousa; Danilo D A Fonseca Reis Silva; Joao Victor Machado Alessi; Max Senna Mano Journal: Ecancermedicalscience Date: 2016-01-07
Authors: J A Garcia-Saenz; B Bermejo; L G Estevez; A G Palomo; X Gonzalez-Farre; M Margeli; S Pernas; S Servitja; C A Rodriguez; E Ciruelos Journal: Clin Transl Oncol Date: 2015-10-26 Impact factor: 3.405